Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Specialty drug company Mylan is shelling out $750 million to buy several female health care businesses from Mumbai-based Famy Care. Famy, a leader in generic oral contraceptives, has been a marketing partner of Mylan since 2008. In a separate deal, Mylan will pay Theravance Biopharma $15 million for access to TD-4208, a treatment for chronic obstructive pulmonary disease. Theravance expects to begin Phase III studies on TD-4208, a once-daily nebulized muscarinic antagonist, this year. Mylan is also taking a $30 million stake in the biotech firm.
This article has been sent to the following recipient: